17-05-2012 дата публикации
Номер: US20120122875A1
The pharmaceutically acceptable salts of methyl (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine--carboxylate, their preparation methods and their use for preparing anti-diabetic medicaments are disclosed. 1. A composition comprising:a pharmaceutically acceptable salt of (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic methyl ester.2. The composition according to claim 1 , wherein the pharmaceutically acceptable salt comprises an inorganic salt.3. The composition according to claim 2 , wherein the inorganic salt is selected from the group consisting of phosphate salt claim 2 , hydrochloride salt claim 2 , sulfate salt claim 2 , nitrate salt or hydrobromide salt.4. The composition according to claim 4 , wherein the pharmaceutically acceptable salt comprises an organic salt.5. The composition according to claim 1 , wherein the organic salt is selected from the group consisting of mesylate salt claim 1 , maleate salt claim 1 , tartrate salt claim 1 , succinate salt claim 1 , acetate salt claim 1 , trifluoroacetate salt claim 1 , fumarate salt claim 1 , citrate salt claim 1 , benzene sulfonate salt claim 1 , benzoate salt claim 1 , naphthalenesulfonate salt claim 1 , lactate salt claim 1 , and malate salt.6. A method comprising:salifying (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic methyl ester with a corresponding acid, the salifying producing a pharmaceutically acceptable salt of (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic methyl ester.7. The method according to claim 6 , further comprising combining a therapeutically effective amount of the pharmaceutically acceptable salt of (R)-7-[3-amino-4-(2 claim 6 ,4 claim 6 ,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5 claim 6 ,6 ...
Подробнее